Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Dec
05
Today In Oncology
Total Neoadjuvant Therapy and Nonoperative Management in pMMR/MSS Stage II to III Rectal Cancer
Fuzuloparib in HER2-Negative Metastatic Breast Cancer With Germline BRCA1/2 Mutations
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
ASCO Statement on Departure of Richard Pazdur From FDA
Mammography-Based Outreach Increases Lung Cancer Screening Enrollment in Eligible Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo